Clinical Trial Update: A Study to Compare Uliledlimab Combined With Toripalimab, Toripalimab Monotherapy, and Pembrolizumab Monotherapy in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1- and CD73- Selected Non-Small Cell Lung Cancer [Phase 2, Phase 3]

View source ↗

Summary

Clinical trial update for a study comparing Uliledlimab plus Toripalimab, Toripalimab monotherapy, and Pembrolizumab monotherapy in previously untreated locally…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Pembrolizumab (pembrolizumab)
• Toripalimab (Toripalimab)
• Uliledlimab (uliledlimab)

Snippet

Sponsor: TJ Biopharma Co., Ltd. | Conditions: Non Small Cell Lung Cancer | Phase 2, Phase 3 | Status: ACTIVE_NOT_RECRUITING